Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with G / Granisetron

A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]
Serotonin Antagonists
ManufacturersStrakan international ltd
Akorn inc
App pharmaceuticals llc
Baxter healthcare corp anesthesia and critical care
Bedford laboratories
Claris lifesciences ltd
Dr reddys laboratories inc
Ebewe pharma
Sagent strides llc
Sandoz canada inc
Teva parenteral medicines inc
Watson laboratories inc
Wockhardt usa inc
App pharmaceuticals
Hikma farmaceutica (portugal) sa
Hoffmann la roche inc
Cypress pharmaceutical inc
Apotex inc
Barr laboratories inc
Cipla ltd
Corepharma llc
Dr reddys laboratories ltd
Mylan pharmaceuticals inc
Natco pharma ltd
Orchid healthcare
Roxane laboratories inc
Taro pharmaceuticals usa inc
Teva pharmaceuticals usa
PackagersAkorn Inc.
Amerigen Pharmaceuticals Inc.
Apotex Inc.
APP Pharmaceuticals
Ascend Laboratories LLC
Aveva Drug Delivery Systems Inc.
Baxter International Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Cipla Ltd.
Corepharma LLC
Cura Pharmaceutical Co. Inc.
DAVA Pharmaceuticals
Doctor Reddys Laboratories Ltd.
Ebewe Pharma
F Hoffmann La Roche Ltd.
F Hoffmann-La Roche Ltd.
GlaxoSmithKline Inc.
Hawthorn Pharmaceuticals
Hikma Pharmaceuticals
Neuman Distributors Inc.
Northstar Rx LLC
Orchid Healthcare
Physicians Total Care Inc.
Prostrakan Inc.
Roxane Labs
Taro Pharmaceuticals USA
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
West-Ward Pharmaceuticals
Wockhardt Ltd.
Granisetron base
Granisetron HCl
Granisetron hydrochloride
Granisetronum [INN-Latin]


For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).


Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.

mechanism of action

Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.


LD50>2000 mg/kg (rat, oral)


Primarily hepatic; undergoes N -demethylation and aromatic ring oxidation followed by conjugation. Animal studies suggest that some of the metabolites may have 5-HT 3 receptor antagonist activity.


Absorption of is rapid and complete, though oral bioavailability is reduced to about 60% as a result of first pass metabolism.

half life

4-6 hours in healthy patients, 9-12 hours in cancer patients

route of elimination

The remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.